WAILEA, Hawaii — Dupilumab is an important treatment for patients with atopic dermatitis, but there can be ocular consequences, which themselves need treatment.
Approximately 10% of patients taking Dupixent (dupilumab, Sanofi/Regeneron) report eye issues, including conjunctivitis, keratitis, blepharitis, pruritus and dry eye, Francis S. Mah, MD, said in a panel discussion at Hawaiian Eye 2021.
Although ocular inflammation does appear to resolve when treatment is stopped, stopping treatment is a difficult choice for some patients because it works so well for their dermatologic problems.
“I